Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GLPG 3121

Next Previous
Drug Profile

GLPG 3121

Alternative Names: GLPG-3121

Latest Information Update: 11 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galapagos NV
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 05 Aug 2022 Discontinued - Phase-I for Inflammation (In volunteers) in Germany, Belgium (PO)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Belgium (PO, Suspension)
  • 08 Nov 2021 Galapagos NV completes a phase I trial in Inflammation (In volunteers) in Germany (NCT04856358) (EudraCT2020-004174-21)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top